It has received approval from both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of adults with advanced bladder cancer who have previously undergone platinum-based chemotherapy and PD(L)-1 inhibitors (Talukder et al., 2023). This evidence concerns the gene CD274 and urinary bladder carcinoma.